Shimon Slavin

Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic γδT Cell Therapies Addressing Solid Tumors

Retrieved on: 
Wednesday, October 27, 2021

Takeda exercised its option to acquire GammaDelta for a pre-negotiated upfront payment as well as potential development and regulatory milestones.

Key Points: 
  • Takeda exercised its option to acquire GammaDelta for a pre-negotiated upfront payment as well as potential development and regulatory milestones.
  • The acquisition follows a multi-year collaboration between Takeda and GammaDelta Therapeutics formed in 2017 to develop GammaDeltas novel T cell therapy platforms, in which Takeda received an equity stake and an exclusive right to purchase GammaDelta.
  • GammaDelta Therapeutics (GammaDelta) is clinically-staged biotechnology company pioneering the discovery and development of allogeneic gamma delta T cell therapies for cancer.
  • GammaDelta is advancing its novel, T cell platforms and product candidates under an ongoing collaboration with Takeda Pharmaceutical Company Limited (Takeda).

FDA Gives Green Light for Multiple Sclerosis Stem Cell Trial

Retrieved on: 
Tuesday, July 27, 2021

Non-profit research organization Hope Biosciences Stem Cell Research Foundation (HBSCRF) has received FDA authorization for a randomized, double-blind, single center, Phase II clinical trial to assess the efficacy of multiple intravenous infusions of autologous adipose-derived mesenchymal stem cells in improving symptoms and quality of life in patients with mild-to-moderate multiple sclerosis (MS).

Key Points: 
  • Non-profit research organization Hope Biosciences Stem Cell Research Foundation (HBSCRF) has received FDA authorization for a randomized, double-blind, single center, Phase II clinical trial to assess the efficacy of multiple intravenous infusions of autologous adipose-derived mesenchymal stem cells in improving symptoms and quality of life in patients with mild-to-moderate multiple sclerosis (MS).
  • A single infusion in the treatment group consists of 200 million stem cells, or approximately 1.2 billion stem cells per patient over the course of study.
  • HBSCRF remains the only organization globally to administer pure, fresh mesenchymal stem cells, an adult stem cell harvested from fat, in such high quantities over repeat treatments.
  • Clinical trial authorizations encompass COVID-19 prevention and treatment , traumatic brain injury , Parkinsons disease , and multiple sclerosis.

BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update

Retrieved on: 
Monday, July 26, 2021

The NurOwn technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders.

Key Points: 
  • The NurOwn technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders.
  • MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.
  • About BrainStorm Cell Therapeutics Inc.
    BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.
  • BrainStorm completed under an investigational new drug application a Phase 2 open-label multicenter trial (NCT03799718) of autologous MSC-NTF cells in progressive multiple sclerosis (MS).

Global Regenerative Medicines Market 2020-2030: Opportunities in Drug Approvals and Strong Pipeline of Cell and Gene Therapies & Multiple Investments in Expansion of cGMP Units - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 15, 2021

Cell and gene therapies, though advancing at a rapid pace, have primarily been targeted for hematological malignancies.\nHowever, the same potential has not been replicated in solid tumor applications, consequently creating demand for cell therapies focusing on solid tumors.

Key Points: 
  • Cell and gene therapies, though advancing at a rapid pace, have primarily been targeted for hematological malignancies.\nHowever, the same potential has not been replicated in solid tumor applications, consequently creating demand for cell therapies focusing on solid tumors.
  • Such trends are consistently propelling the industry toward realizing the true potential of precision medicine.\nWithin the research report, the market is segmented on the basis of products, applications, and region.
  • Major manufacturers of regenerative medicine products are actively involved in undertaking significant business strategies in order to translate success in research and development into the commercial clinical setting.
  • Although tissue engineering and stem cells remain the dominating product segments, the advent of cell and gene therapy has revolutionized the regenerative medicine phenomenon, moving it more toward the precision medicine space.\n'

Company Profile for AlloVir

Retrieved on: 
Thursday, December 10, 2020

AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened immune systems.

Key Points: 
  • AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened immune systems.
  • The companys innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viruses for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases.
  • AlloVirs technology and manufacturing process enables the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy.
  • The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.

IN8bio announces first-in-human Phase 1 trial Update from The University of Kansas Cancer Center using INB-100, IN8bio’s Gamma Delta T-cell product candidate, at ASH 2020

Retrieved on: 
Thursday, December 3, 2020

INB-100 is designed for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation with haploidentical donors.

Key Points: 
  • INB-100 is designed for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation with haploidentical donors.
  • Dr. McGuirk, commented, Potentially curative stem cell transplants using partially matched donors -- called haploidentical transplants have greatly expanded access to stem cell transplantation.
  • The infusion of donor-derived gamma delta T-cells from the stem cell donor, offers the hope of diminishing this risk of relapse and curing more patients.
  • IN8bios technology incorporates drug-resistant immunotherapy (DRI), which has been shown in preclinical studies to function in combination with therapeutic levels of chemotherapy.

Wugen Appoints New Vice President and Head of NK Research as the Company Continues to Expand its Pipeline

Retrieved on: 
Thursday, November 19, 2020

ST. LOUIS, Nov. 19, 2020 /PRNewswire/ --Wugen Inc., a biotechnology company developing a novel, universal allogeneic CAR-T therapy platform, today announced the appointment of Ryan Sullivan, Ph.D., as Vice President and Head of NK Research.

Key Points: 
  • ST. LOUIS, Nov. 19, 2020 /PRNewswire/ --Wugen Inc., a biotechnology company developing a novel, universal allogeneic CAR-T therapy platform, today announced the appointment of Ryan Sullivan, Ph.D., as Vice President and Head of NK Research.
  • "Ryan has a deep understanding of Natural Killer cells and a decade of outstanding oncology research experience.
  • Dr. Sullivan added "I am delighted to join Wugen's impressive team and look forward to leading the company's NK research programs.
  • Wugen Inc., is a biotechnology company developing a novel CAR-T therapy platform including an "off-the-shelf" fratricide-resistant CAR-T cell therapy for T-cell malignancies.

Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences

Retrieved on: 
Monday, November 16, 2020

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today announced that Company management will participate at two upcoming virtual conferences.

Key Points: 
  • Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today announced that Company management will participate at two upcoming virtual conferences.
  • Archived replays will be available on the Company's website for approximately 14 days following the live webcasts.
  • Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease.
  • Atara is headquartered in South San Francisco and our leading-edge research, development and manufacturing facility is based in Thousand Oaks, California.

Qihan Biotech Unveils its Program to Develop Immunologically Privileged Human Stem Cells for Allogeneic Cell Therapies

Retrieved on: 
Wednesday, October 14, 2020

Qihan Biotech, a leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, today disclosed the initiation of a program to create immunologically privileged human stem cells to enable the development of improved allogeneic cell therapies.

Key Points: 
  • Qihan Biotech, a leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, today disclosed the initiation of a program to create immunologically privileged human stem cells to enable the development of improved allogeneic cell therapies.
  • Once differentiated into different cell types, the cells have the potential to be used as universal, allogeneic therapies while reducing or eliminating the need for the patient to receive immunosuppressive drugs.
  • To address these obstacles and realize the full potential of allogeneic cell therapies, the Qihan team is using our proprietary multiplexable gene editing technology, in combination with our extensive expertise in transplantation immunology, to create immunologically privileged human stem cells.
  • Qihan Biotech is a biotechnology company applying genome-editing technology to develop novel cell therapies and organs for transplantation.

Gamida Cell Announces Positive Topline Data on Secondary Endpoints from Phase 3 Clinical Study of Omidubicel in Patients with Hematologic Malignancies

Retrieved on: 
Tuesday, October 6, 2020

All three secondary endpoints demonstrated a statistically significant improvement among patients who received omidubicel compared to the comparator group.

Key Points: 
  • All three secondary endpoints demonstrated a statistically significant improvement among patients who received omidubicel compared to the comparator group.
  • These additional data reinforce the potential of omidubicel and move us another step closer toward bringing potentially curative therapies to patients.
  • Omidubicel is an advanced cell therapy under development as a potential life-saving allogeneic hematopoietic stem cell (bone marrow) transplant solution for patients with hematologic malignancies (blood cancers).
  • 4Gamida Cell press release, Gamida Cell Announces Positive Topline Data from Phase 3 Clinical Study of Omidubicel in Patients with High-Risk Hematologic Malignancies, issued May 12, 2020.